ANIP NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

ANI Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data Download investor PDF
Latest close 77.65 USD
-2.0% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -1.8% below the Trend Line and sits at 40.8% of its 52-week range. The latest completed week returned -2.0%, after a -8.1% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 38/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 8d.

Setup score 34 out of 100
Latest Close 77.65 USD 24 Jul 2026
1W Return -2.0% latest completed week
4W Return -8.1% short-term follow-through
12W Return -3.4% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.0% Latest completed week; four-week move -8.1%. Indicator stack 41/49 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 38/100 conviction; expected move 11.4%. News sentiment 56/100 41 relevant articles in the latest sentiment read. Event risk 8d Next report is scheduled for 07 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -1.8% below the Trend Line and sits at 40.8% of its 52-week range. The latest completed week returned -2.0%, after a -8.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5012-week average 0.25

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.50Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.1% over four weeks, -3.4% over 12 weeks, and 15.1% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W-2.0%
4W-8.1%
12W-3.4%
26W-6.4%
52W15.1%
Active trend streak4 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.26Latest activity-pressure read.
Pressure change-70.1%Four-week change in activity pressure.
Leadership-14.21Latest relative-leadership reading.
RS change-45.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 97% Model confidence 93%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength92/100Blend of value, momentum, and quality. Underlying universe rank 9; rank 1 is best.
Value74/100Relative valuation strength. Underlying universe rank 27; rank 1 is best.
Quality97/100Profitability and accounting quality. Underlying universe rank 4; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth85/100Revenue and earnings growth. Underlying universe rank 16; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework75/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
19.7x
Price divided by trailing earnings.
Price / sales
1.9x
Market value relative to trailing revenue.
EV / EBITDA
7.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
14.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
65.9%
Gross profit retained from each unit of revenue.
Operating margin
15.7%
Operating profit retained from revenue.
Free-cash-flow margin
27.8%
Free cash flow generated from revenue.
Return on invested capital
19.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
37.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
128.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
0.7%
Net share repurchases relative to market value.
Shareholder yield
0.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

ANIP shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.50, expected move of 11.4%, and Sharemaestro trend signal active.

Conviction38/100
Expected move11.4%
Put/call volume0.50
Pressure45
Speculation1
Volatility83
Trend agreement41
Open options detail
Insider activity7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 41 relevant articles.

13 positive · 22 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings8dNext report is scheduled for 07 Aug 2026; event risk rises as the date approaches.
Options expected move11.4%Nearest-chain priced movement where available.
52-week drawdown-22.0%Distance below the 52-week high.
13-week volatility3.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+6.3%Week of 26 Jun.
Worst week-5.5%Week of 13 Feb.
Latest week-2.0%Week of 24 Jul.

Shape of recent returns

Strong gains4
Modest gains9
Flat weeks0
Modest losses7
Sharp losses6
Recent vol3.8%13-week weekly-return volatility.
Base vol5.6%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew4.7% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape36/100

Trend, activity pressure, participation, and risk combine to a 36/100 tape read.

 Indicator analysis47/100

Latest 12-week confirmation: trend 4/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.50; No reversal markers Factors83/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 33; Small Cap Core rank 38 SVQF75/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 179.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options52/100

ANIP shows bullish options pressure with a 38/100 conviction score, put-call volume ratio of 0.50, expected move of 11.4%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 11.4% Sentiment56/100

Weighted news tone is neutral across 41 relevant articles.

Is ANI Pharmaceuticals (ANIP) A Bargain Following Its Positive SYNCHRONICITY Trial Results? Insiders7 / 13

7 acquisitions and 13 disposals in the latest 180-day insider tape.

 Earnings8d

Next report is scheduled for 07 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202677.65 USD-2.0%79.09 USD68.07 USD0.26-14.211.2MOn
17 Jul 202679.20 USD-3.5%79.25 USD67.91 USD0.75-13.971.5MOn
10 Jul 202682.07 USD-4.6%79.37 USD67.74 USD0.92-14.621.4MOn
3 Jul 202686.03 USD1.8%79.31 USD67.54 USD0.93-8.941.4MOn
26 Jun 202684.50 USD6.3%79.17 USD67.32 USD0.85-9.752.2MOff
19 Jun 202679.49 USD-2.7%79.18 USD67.12 USD0.60-18.931.3MOff
12 Jun 202681.68 USD0.7%79.19 USD66.94 USD0.70-14.681.1MOff
5 Jun 202681.11 USD3.3%79.27 USD66.75 USD0.69-13.401.8MOff
29 May 202678.51 USD-5.1%79.58 USD66.55 USD0.76-19.981.4MOff
22 May 202682.72 USD6.0%79.98 USD66.35 USD0.72-13.331.7MOff
15 May 202678.01 USD-4.7%80.36 USD66.12 USD0.43-17.262.3MOff
8 May 202681.86 USD1.8%80.92 USD65.91 USD0.37-13.532.7MOff
1 May 202680.39 USD2.2%81.19 USD65.65 USD0.13-10.681.2MOff
24 Apr 202678.64 USD-2.8%81.50 USD65.39 USD-0.18-11.661.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.